Fusion Antibodies logo

FAB - Fusion Antibodies Share Price

105p 2.5  2.4%

Last Trade - 29/05/20

Sector
Healthcare
Size
Micro Cap
Market Cap £26.7m
Enterprise Value £25.7m
Revenue £3.28m
Position in Universe 1285th / 1825
Bullish
Bearish
Unlock FAB Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the six months ended 30 September 2019, Fusion Antibodies PLC revenues increased from £658K to £1.8M. Net loss decreased 36% to £473K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -£0.03 to -£0.02.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

FAB Revenue Unlock FAB Revenue

Net Income

FAB Net Income Unlock FAB Revenue

Normalised EPS

FAB Normalised EPS Unlock FAB Revenue

PE Ratio Range

FAB PE Ratio Range Unlock FAB Revenue

Dividend Yield Range

FAB Dividend Yield Range Unlock FAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
FAB EPS Forecasts Unlock FAB Revenue
Profile Summary

Fusion Antibodies PLC, formerly Fusion Antibodies, Ltd., is a United Kingdom-based cancer therapeutics developer. The Company develops and commercializes antibody-based therapeutics for cancer. The Company develops a range of antibody engineering services based around monoclonal antibodies. It focuses in the expression and purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. Its technology generates target specific antibodies from protein antigens. The Company's therapeutic and diagnostic research and development are offered as a service to pharmaceutical, biopharmaceutical and academic researchers.

Directors
Last Annual March 31st, 2019
Last Interim September 30th, 2019
Incorporated November 29, 2000
Public Since December 18, 2017
No. of Shareholders: n/a
No. of Employees: 30
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 25,424,525
Free Float (0.0%)
Eligible for
ISAs
SIPPs
FAB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FAB
Upcoming Events for FAB
Frequently Asked Questions for Fusion Antibodies
What is the Fusion Antibodies share price?

As of 29/05/20, shares in Fusion Antibodies are trading at 105p, giving the company a market capitalisation of £26.7m. This share price information is delayed by 15 minutes.

How has the Fusion Antibodies share price performed this year?

Shares in Fusion Antibodies are currently trading at 105p and the price has moved by 82.61% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fusion Antibodies price has moved by 0.108k% over the past year.

What are the analyst and broker recommendations for Fusion Antibodies?

Of the analysts with advisory recommendations for Fusion Antibodies, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Fusion Antibodies is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Fusion Antibodies next release its financial results?

Fusion Antibodies is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Fusion Antibodies dividend yield?

Fusion Antibodies does not currently pay a dividend.

Does Fusion Antibodies pay a dividend?

Fusion Antibodies does not currently pay a dividend.

When does Fusion Antibodies next pay dividends?

Fusion Antibodies does not currently pay a dividend.

How do I buy Fusion Antibodies shares?

To buy shares in Fusion Antibodies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Fusion Antibodies?

Shares in Fusion Antibodies are currently trading at 105p, giving the company a market capitalisation of £26.7m.

Where are Fusion Antibodies shares listed? Where are Fusion Antibodies shares listed?

Here are the trading details for Fusion Antibodies:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: FAB
What kind of share is Fusion Antibodies?

Based on an overall assessment of its quality, value and momentum, Fusion Antibodies is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Fusion Antibodies share price forecast 2020?

We were not able to load any forecast data for Fusion Antibodies.

How can I tell whether the Fusion Antibodies share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusion Antibodies. Over the past six months, the relative strength of its shares against the market has been 64.38%. At the current price of 105p, shares in Fusion Antibodies are trading at 28.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Fusion Antibodies PE Ratio?

We were not able to find PE ratio data for Fusion Antibodies.

Who are the key directors of Fusion Antibodies?

Fusion Antibodies's management team is headed by:

Simon Douglas - CEO
James Johnston - CSO
John Ivan George Cadogan - CHM
John Maynard - DRC
Alan Mawson - DRC
Who are the major shareholders of Fusion Antibodies?

Here are the top five shareholders of Fusion Antibodies based on the size of their shareholding:

Crescent Capital NI Limited Venture Capital
Percentage owned: 13.31% (3.38m shares)
Amati Global Investors Limited Investment Advisor
Percentage owned: 9.21% (2.34m shares)
Clarendon Fund Managers Limited Venture Capital
Percentage owned: 8.62% (2.19m shares)
Octopus Investments Limited Investment Advisor
Percentage owned: 6% (1.53m shares)
Canaccord Genuity Wealth Management Investment Advisor/Hedge Fund
Percentage owned: 5.52% (1.40m shares)
Similar to FAB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.